BioVie exploring potentially pivotal trial for NE3107
BioVie is exploring a potentially pivotal Phase 3 clinical trial to test its experimental oral therapy NE3107 in people with Parkinson’s disease. “Throughout the past several months, data reported or presented at major medical conferences have established a compelling rationale for further clinical evaluation of NE3107 in Parkinson’s Disease,”…